AbbVie (ABBV) shows strong 5-year growth (120%) but trades at a higher P/E of 18.69 and a low 2.64% yield, making it appear expensive relative to its peers.
Source Post
Lock In 6%+ Yields Before These Healthcare Stocks Soar!
Aug 23, 2026
The Dividend Diplomats discuss the healthcare and pharmaceutical industry, noting a recent bump due to positive vaccine testing results for Moderna. They analyze three stocks, Pfizer, Avy, and Merck, to determine if they are good buys, focusing on valuation, dividend safety, growth, and yield. The first stock analyzed is Pfizer (PFE).
Linked Mentions
Tickers discussed in this post
GlaxoSmithKline (GSK) has a P/E ratio of 10.94, a safe 38% payout ratio, and a 3.5% dividend yield, with dividend growth resuming after a merger-related pause.
Pfizer (PFE) is presented as a buy due to its low P/E ratio under 10, a strong dividend yield over 6%, and a safe payout ratio, suggesting it's undervalued.
Linked Signals
Tracked calls opened from this post
PFEbuy opened Aug 23, 2026
+6.16%